Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Nov 6;12(11):1320.
doi: 10.3390/pathogens12111320.

Participation of Single-Nucleotide Variants in IFNAR1 and IFNAR2 in the Immune Response against SARS-CoV-2 Infection: A Systematic Review

Affiliations
Review

Participation of Single-Nucleotide Variants in IFNAR1 and IFNAR2 in the Immune Response against SARS-CoV-2 Infection: A Systematic Review

María Fernanda López-Bielma et al. Pathogens. .

Abstract

Host genetic factors significantly influence susceptibility to SARS-CoV-2 infection and COVID-19 severity. Among these genetic factors are single-nucleotide variants (SNVs). IFNAR2 and IFNAR1 genes have been associated with severe COVID-19 in populations from the United Kingdom, Africa, and Latin America. IFNAR1 and IFNAR2 are subunits forming the type I interferon receptor (IFNAR). SNVs in the IFNAR genes impact protein function, affecting antiviral response and disease phenotypes. This systematic review aimed to describe IFNAR1 and IFNAR2 variants associated with COVID-19 susceptibility and severity. Accordingly, the current review focused on IFNAR1 and IFNAR2 studies published between January 2021 and February 2023, utilizing the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) protocol. The electronic search was conducted in PubMed databases using Boolean operators and inclusion and exclusion criteria. Of the 170 literature pieces, 11 studies were included. We include case reports of rare SNVs, defined by minor allele frequency (MAF) < 1%, and genome-wide associated studies (GWAS). Variants in IFNAR1 and IFNAR2 could potentially be new targets for therapies that limit the infection and the resulting inflammation by SARS-CoV-2 infection.

Keywords: COVID-19; IFNAR1; IFNAR2; antiviral response; single-nucleotide variants.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Entry of SARS-CoV-2 into the cell via ACE2 and TMPRSS2. The endosome is formed by double-membrane vesicles where the coronavirus replicates. Viral RNA (ssRNA, dsRNA) is recognized by TLR3, TLR7, RIG-I, and MDA5. These receptors activate TRIF and MyD88, downstream TLRs, and MAVS downstream RIG-I and MDA5, starting in the interferon production pathway. When IRF3, IRF7, or NFkB are activated, they translocate to the nucleus and trigger the transcription of immunogens like inflammatory cytokines and IFN. The dotted line represents the transition to IFN signaling, beginning with IFN-I binding IFNAR to initiate JAK/STAT signaling. In silico assays propose that the A allele of rs2236757 in IFNAR2 increases the affinity of STAT3 to IFNAR1.
Figure 2
Figure 2
Flow diagram for the included studies.

Similar articles

Cited by

References

    1. Órpez-Zafra T., Pavía J., Hurtado-Guerrero I., Pinto-Medel M.J., Bada J.L.R., Urbaneja P., Suardíaz M., Villar L.M., Comabella M., Montalban X., et al. Decreased soluble IFN-β receptor (sIFNAR2) in multiple sclerosis patients: A potential serum diagnostic biomarker. Mult. Scler. J. 2017;23:937–945. doi: 10.1177/1352458516667564. - DOI - PubMed
    1. Bastard P., Hsiao K.-C., Zhang Q., Choin J., Best E., Chen J., Gervais A., Bizien L., Materna M., Harmant C., et al. A loss-of-function IFNAR1 allele in Polynesia underlies severe viral diseases in homozygotes. J. Exp. Med. 2022;219:e20220028. doi: 10.1084/jem.20220028. - DOI - PMC - PubMed
    1. Murphy K., Travers P., Walport M. Janeway’s Immunobiology. Garland Science; New York, NY, USA: 2008.
    1. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 2005;5:375–386. doi: 10.1038/nri1604. - DOI - PubMed
    1. Sodeifian F., Nikfarjam M., Kian N., Mohamed K., Rezaei N. The role of type I interferon in the treatment of COVID-19. J. Med Virol. 2022;94:63–81. doi: 10.1002/jmv.27317. - DOI - PMC - PubMed

LinkOut - more resources